This week’s list of top stocks to watch features CME Group (CME) in a prominent position, accompanied by Meta Platforms (META), Arista Networks (ANET), Paccar (PCAR), and Arch Capital (ACGL).

CME Group and Arch Capital saw a breakout in their stock prices on Friday after bouncing back from crucial technical support.

Arista and Paccar marked early entries, while Meta Platforms, the parent company of Facebook and Instagram, experienced a clear breakout.

All of these stocks, except CME, hold positions on the IBD 50 list of top growth stocks, showcasing their growth potential. Meta and ANET stock are also part of the IBD Leaderboard, further highlighting their strong market presence.

A notable commonality among these stocks is their relative strength lines, which are at 52-week highs, indicating robust outperformance compared to the S&P 500. This relative strength is depicted by the blue line in the charts provided.

Most of these top stocks can be found on the MarketSmith RS Line Blue Dot screen, a list that comprises stocks in bases or breaking out with RS lines at new highs—an encouraging sign for investors.

Stocks meeting these criteria are marked with a blue dot at the end of their RS lines in the MarketSmith charts.

Investors are advised to actively seek stocks demonstrating relative strength, rebounding from crucial levels, or making significant comebacks.

Despite the stock market’s enduring challenges, Friday’s upswing in stronger volume offered a glimmer of hope.

CME Group, the futures exchange operator, witnessed a 2.2% rise in shares on Friday, reaching 211.93 and surpassing the 209.31 buy point intraday.

The stock experienced a remarkable 5.85% surge for the week. Notably, it reacquired the 50-day/10-week moving averages, achieving several gains in above-average volume.

On October 3, CME Group reported an average daily volume (ADV) of 22.7 million contracts in September, marking the second-highest September ADV on record. Additionally, its Q3 ADV of 22.3 million contracts was the second-highest Q3 volume ever recorded.

In terms of key IBD ratings, CME Group stands strong. It boasts an IBD Composite Rating of 92, an EPS Rating of 87, and an RS Rating of 90—each out of a best-possible 99.

The 90 Relative Strength Rating signifies that CME stock has outperformed 90% of all stocks listed in IBD’s database over the past 12 months.